Clinical Trial Update: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update: imetelstat is being studied versus best available therapy in intermediate-2 or high-risk myelofibrosis patients who have not resp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Imetelstat (imetelstat)

Snippet

Sponsor: Geron Corporation | Conditions: Myelofibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING